Dr. Annemarie Dedek receives $100,000 from Brain Canada’s Future Leaders in Canadian Brain Research to to advance chronic pain research.
Dr. William Wong has received over $852,000 in funding from the Canadian Institutes of Health Research (CIHR) to develop new tools for identifying people living with undiagnosed hepatitis C over the course of four years.
Dr. Emmanuel Ho, professor at the University of Waterloo School of Pharmacy, has received support through the Centre for Aging + Brain Health Innovation’s (CABHI) Ignite program to advance an innovative mobile screening tool that aims to detect early signs of eye disease and potential changes in cognitive health.
The University of Waterloo and Schlegel-UW Research Institute for Aging (RIA) are pleased to announce that Dr. Tejal Patel, Associate Professor at the University of Waterloo’s School of Pharmacy, has been appointed as Schlegel Chair in Medication Management and Aging.
Canadian Cancer Society and MaRS grant $100,000 to Gateway CERH in partnership with the School of Pharmacy
A new study finds that combining the current medications for Alzheimer’s disease with small molecules derived from micronutrients found in grapes, berries, peanuts and turmeric is a safer and more effective way to treat the disease.
Over $189,000 has been awarded to enable the expansion of a vaccine decision tool for healthcare professionals tailored to cancer patients’ needs.
Ontario is investing $1.8 billion to pair Waterloo Region residents with a family doctor or primary care team, multidisciplinary groups that include physicians, nurses, pharmacists, social workers, physiotherapists and dieticians. Pharmacists play a large role in primary care and as their scope continues to grow, they can put their knowledge into practice to provide better services for improved care.
Volume 35 of the Medicinal Chemistry Research journal cover features art compiled by University of Waterloo School of Pharmacy student Rahul Karuturi (PhD’25) for their research, Synthesis and evaluation of symmetric (1,4-diazepane-1,4-diyl)bis(phenylmethanone) derivatives as amyloid-beta aggregation inhibitors.
Dr. Wajd Alkabbani awarded $481,950 to assess how health policy, social factors and medical conditions affect who gets access to continuous glucose monitoring (CGM) devices in Canada and how well it works in preventing serious health problems.